The burden of asthma falls disproportionately on vulnerable groups including racial/ethnic minorities and children. Enhancing the clinical infrastructure for comparative effectiveness research in asthma and lung diseases will have high impact because there is a continuing dearth of information to address current medication choices for these priority populations. To reduce asthma morbidity, we also need to better elucidate the factors that affect prescribing and adherence to asthma controller medications in diverse populations.
Specific Aims - We will: (1) Build an innovative infrastructure for research on asthma and lung diseases by creating and linking standardized datasets from a state Medicaid population and four health plan populations;(2) Compare real-world adherence to and effectiveness of the major asthma controller regimens in diverse populations;and (3) Conduct an applied methodologic study that compares different design and analysis approaches for observational comparative effectiveness research. Research Design - For Aim 1, we will create a new distributed data network for research in asthma and lung diseases by building on extensive, currently available computerized datasets from our diverse populations - the TennCare Medicaid population and four HMO Research Network sites. We will build on the HMORN's Virtual Data Warehouse `and approaches used by other successful networks.
For Aim 2, we will conduct cohort and nested case-control studies using data from claims, electronic medical records (EMRs), and surveys of patients and providers.
Aim 2 analyses will evaluate variations in the rates of adverse asthma outcomes and costs among the major controller regimens, using propensity score weighting and alternative methods to adjust for confounding by indication.
For Aim 3, we will conduct a methodologic study that compares the generalizability and validity of various study designs and statistical analysis approaches, and evaluates the benefits of collecting patient-reported data. Impact. This project is innovative in its plan to include all four important data sources - claims, EMRs, patients, and providers - and a state Medicaid population in a new network for comparative effectiveness research on asthma and lung diseases. This large, diverse network will create a seminal model for comparative effectiveness research in chronic diseases and vulnerable populations. The current project will address key clinical and policy questions in asthma. The PEAL Network will lay a critical foundation for future population-based research in asthma and lung diseases, and research with priority populations.

Public Health Relevance

Project Narrative This project will create a new infrastructure to accelerate comparative effectiveness research in asthma and other lung diseases in diverse populations. We will form the Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network, creating highly detailed, standardized, linked computerized datasets from a state Medicaid plan and four health plans. We will conduct comparative effectiveness research on asthma controller medications, evaluating adherence and other real-world factors. This project is innovative in that we will link claims, electronic medical record, patient, and provider data, and will build new linkages with a Medicaid plan to include vulnerable groups who are disproportionately burdened by asthma.

Agency
National Institute of Health (NIH)
Institute
Agency for Healthcare Research and Quality (AHRQ)
Type
Research Project (R01)
Project #
1R01HS019669-01
Application #
8019300
Study Section
Special Emphasis Panel (ZHS1-HSR-A (04))
Program Officer
Randhawa, Gurvaneet
Project Start
2010-09-30
Project End
2013-09-29
Budget Start
2010-09-30
Budget End
2013-09-29
Support Year
1
Fiscal Year
2010
Total Cost
Indirect Cost
Name
Harvard Pilgrim Health Care, Inc.
Department
Type
DUNS #
071721088
City
Boston
State
MA
Country
United States
Zip Code
02215
Turi, Kedir N; Gebretsadik, Tebeb; Lee, Rees L et al. (2018) Seasonal patterns of Asthma medication fills among diverse populations of the United States. J Asthma 55:764-770
Stone, Cosby; Gebretsadik, Tebeb; Lee, Rees L et al. (2018) Trends in health care utilization for asthma exacerbations among diverse populations with asthma in the United States. J Allergy Clin Immunol Pract 6:295-297.e5
Wu, Ann Chen; Li, Lingling; Fung, Vicki et al. (2016) Mismatching Among Guidelines, Providers, and Parents on Controller Medication Use in Children with Asthma. J Allergy Clin Immunol Pract 4:910-6
Valet, Robert S; Gebretsadik, Tebeb; Minton, Patricia A et al. (2015) Prevalence and characteristics of medication sharing behavior in a pediatric Medicaid population with asthma. Ann Allergy Asthma Immunol 114:151-3
Wu, Ann Chen; Butler, Melissa G; Li, Lingling et al. (2015) Primary adherence to controller medications for asthma is poor. Ann Am Thorac Soc 12:161-6
Lu, Christine Y; Zhang, Fang; Lakoma, Matthew D et al. (2015) Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. Clin Ther 37:1280-91
Li, Lingling; Vollmer, William M; Butler, Melissa G et al. (2014) A comparison of confounding adjustment methods for assessment of asthma controller medication effectiveness. Am J Epidemiol 179:648-59
Fung, Vicki; Graetz, Ilana; Galbraith, Alison et al. (2014) Financial barriers to care among low-income children with asthma: health care reform implications. JAMA Pediatr 168:649-56
Wu, Ann Chen; Li, Lingling; Fung, Vicki et al. (2014) Use of leukotriene receptor antagonists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids. J Allergy Clin Immunol Pract 2:607-13
Miller, E Kathryn; Gebretsadik, Tebeb; Carroll, Kecia N et al. (2013) Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years. Pediatr Infect Dis J 32:950-5

Showing the most recent 10 out of 13 publications